Pentostatin

DB00552
Approved Indication

For the treatment of hairy cell leukaemia refractory to alpha interferon.

1 Targets
0 Resistance Mutations
0 References
3D Structure No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action

Pentostatin is a potent transition state inhibitor of adenosine deaminase (ADA), the greatest activity of which is found in cells of the lymphoid system. T-cells have higher ADA activity than B-cells, and T-cell malignancies have higher activity than B-cell malignancies. The cytotoxicity that results from prevention of catabolism of adenosine or deoxyadenosine is thought to be due to elevated intracellular levels of dATP, which can block DNA synthesis through inhibition of ribonucleotide reductase. Intracellular activation results in incorporation into DNA as a false purine base. An additional cytotoxic effect is related to its incorporation into RNA. Cytotoxicity is cell cycle phase-specific (S-phase).

Details
DrugBank ID DB00552 ↗
Approval Date 1991-10-11
Molecular Weight 268.2691 g/mol
Drug Class Other
ATC Codes L01XX08
Synonyms Co-vidarabine, Pentostatin, Pentostatina
SMILES
OC[C@H]1O[C@H](C[C@@H]1O)N1C=NC2=C1N=CNC[C@H]2O
ADMET Profile
Computing properties…